Breaking News, Promotions & Moves

Peptone Appoints Kevin Tyler Sprott as COO

Throughout his career, Sprott has played a vital role in the development of more than 10 INDs and clinical-stage assets across several leading companies.

Author Image

By: Charlie Sternberg

Associate Editor

Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases, has appointed Kevin Tyler Sprott, PhD, as Chief Operating Officer. “Peptone is poised to take a significant step forward in our drug discovery and development journey as we leverage the power of experimental physics, supported by AI-driven protein dynamics modelling and innovative technologies like HDX-MS, while also fostering strategic partnerships that amplify...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters